Pfizer Inc. (NYSE:PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50abstracts, including 11oral presentations, will be presented from Pfizer's broadened portfolio of approved and pipeline therapies across the company's key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies.
Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.